FDA Extends Comment Period on Compounded Ozempic
Published Date: 6/26/2026
Notice
Summary
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA proposes excluding three GLP‑1 drugs
The FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the Section 503B "Bulks List" of active ingredients that outsourcing pharmacies can use for compounding. Comments on that proposal will help the FDA decide whether to include these drugs on the 503B Bulks List in its final decision.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19921, Determination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 500 mg sulfadiazine tablet wasn’t taken off the market because it was unsafe or didn’t work. This means generic drug makers can now apply to sell their versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
2026-19850, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503
The FDA is asking for public feedback on how it collects info about food and color additives, including their labels and safety petitions. This affects companies that want to add or change ingredients in food and how they submit their paperwork electronically. Comments are due by October 29, 2026, and the process helps keep food safe without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-12936, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company
Some folks want to buy shares in banks or bank companies, and the Federal Reserve is checking their applications to make sure everything’s fair and safe. If you want to share your thoughts, you’ve got until July 13, 2026, to speak up! This process helps keep banks strong and protects everyone’s money.
Next: 2026-12938, Public Water System Supervision Program Revision for New York; Notice of Approval and Opportunity for Public Comment and Public Hearing
New York has updated its drinking water rules to better protect people from harmful stuff in surface water. The EPA says these new rules meet all federal standards and is ready to approve them, but folks can still share their thoughts or ask for a public hearing by July 27, 2026. This means cleaner water for New Yorkers without extra costs or delays.